Access Constrains Uptake

Retatrutide's clinical profile looks strong, but payers and employers resist broad obesity-drug coverage without clearer long-term cost offsets. Lilly still benefits from the data, but revenue expectations shift toward slower adoption and more prior authorization.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.